Radiopharmaceutical · developed by Regeneron Pharmaceuticals
89Zr-DFO-REGN5054 is a zirconium-89 radiolabeled agent, linked through the chelator desferrioxamine (DFO), built on the REGN5054 molecule.
Summary written with AI from the sources listed at the end of this page.
Advanced Solid TumorMetastatic Solid Tumor
Updated Oct 25, 2026. Something wrong or missing? Report it on the REGN page.
See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
REGN catalysts and pipeline →